The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis ...
[1] 《多肽药物制备工艺研究进展》[2] 《Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP》[3] 《Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing》文中数据及参数均由企业提...
2. Alhomoud IS, Talasaz AH, Chandrasekaran P, et al. Incretin hormone agonists: current and emerging pharmacotherapy for obesity management. Pharmacotherapy, 2024, 44(9): 738-752. 3. Liu QK. Mechanisms of action and therapeutic applications of GLP...
[0009] WO2016/066818描述了对GLP-1和GLP-2受体具有双重激动剂(dualagonist)活性 的肽,并提出了其医学用途。然而,仍需要具有可接受的稳定性水平的组合了对这两种受体 之有效激动剂活性的其他化合物。 [0010] 发明概述 [0011] 概括地说,本发明涉及对GLP-1(胰高血糖素样肽1)和GLP-2(胰高血糖素样肽2)受 ...
[4] Henderson, S.J., Konkar, A., Hornigold, D.C., Trevaskis, J.L., Jackson, R., Fritsch Fredin, M., et al. 2016. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 18:1176-1190. ...
资料来源：Drug Des Devel Ther. Lijing Wang，《Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP》，X技术，国知局，华福研究所 替尔泊肽结构设计基于GLP-1、GIP及艾塞那肽的部分结构、以及增加的特有氨基酸（其中Aib是非天然氨基酸），合成...
最终,Exendin-4(Exenatide/ BYETTA/艾塞那肽)在2005年获得FDA批准,(2009年8月,Byetta/百泌达,在中国获批上市)成为First-in-class的GLP-1类似物,用于2型糖尿病的辅助治疗,每天注射2针(BID)。 由于GLP-1类似物的降糖作用是葡萄糖依赖性的——避免了严重低血糖的风险,同时还被发现具有抑制食欲的作用——具有潜在...
(生物谷Bioon.com) 参考文献 Eun Ran Kim et al. A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome. Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
2. Breaking Boundaries: HRS9531 Pioneers Dual GLP-1/GIP Agonist for Obesity HRS9531 demonstrated a promising result in obese patients with a significant reduction in weight among Chinese adultsin the1861-LBabstract presented at the conference. Treatment using HRS9531, a dual agonist targeting GLP-...
When would I need to take a GLP-1 agonist? Healthcare providersprescribeGLP-1 agonists for two conditions: Type 2 diabetes and obesity. prescribe:开药 GLP-1 agonists for Type 2 diabetes The FDA approves the use of GLP-1 agonists to help manage Type 2 diabetes (T2D). This is because G...